PTC Therapeutics, Inc. has appointed Pierre Gravier Chief Financial Officer. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, an independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development.

Prior Perella Weinberg, Gravier worked as a healthcare investment banker at Barclays Capital in London. Previously, he was a venture capital analyst at Société Générale Asset Management in Paris, where he focused on early-stage investments in the biotechnology sector. Gravier began his career as a scientist at Ferring Pharmaceuticals.

“We are incredibly excited to have Pierre as part of PTC’s leadership team,” said Matthew Klein, CEO, PTC Therapeutics. “Pierre’s extensive global experience in finance and healthcare advisory will be incredibly helpful as we continue to build the PTC of tomorrow. Having known Pierre over the past several years, I am confident his knowledge, experience and passion to help patients make him a great addition to the PTC family.”